Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

Pancreatitis, Acute Clinical Trial

Official title:

Serum Maresin-1 Level Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03364920
• Other study ID #: SMPSSAP
• Status: Not yet recruiting
• Phase: N/A
• First received: November 23, 2017
• Last updated: December 6, 2017
• Start date: January 1, 2018
• Est. completion date: January 1, 2020

Study information

• Verified date: December 2017
• Source: Nanjing University School of Medicine
• Contact: Weiqin Li
• Phone: 13962531994
• Email: luyingying126[@]sina.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: January 1, 2020
• Est. primary completion date: January 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of Severe Acute Pancreatitis

• Biliary pancreatitis

• 7 days of the onset

Exclusion Criteria:

• Surgical patients

• Serious diseases and infection

• Alcoholic pancreatitis

• Hypertriglyceridemia pancreatitis

• Disorder of Glucolipide Metabolism:diabetes mellitus, hypertriglyceridemia, BMI>30

Related Conditions & MeSH terms

• Pancreatitis
• Pancreatitis, Acute

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Weiqin Li

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mortality	The level of serum maresin-1 predicts the severity of severe acute pancreatitis	up to 28 days
Secondary	The incidence of MODS	The level of serum maresin-1 predicts the severity of severe acute pancreatitis	through study completion, an average of 1 year
Secondary	The incidence of IPN	The level of serum maresin-1 predicts the severity of severe acute pancreatitis	through study completion, an average of 1 year